Business
Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results
ZELSUVMI™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total revenue including licensing revenue was $16.8 million for 2025. 8,948 ZELSUVMI units prescribed by 2,712 unique prescribers for fiscal year 2025, with a 129% quarter over quarter increase in units dispensed, rising from 2,716 units in the third quarter of 2025 to 6,232 units in the f
About this update from Pelthos Therapeutics Inc.
[{"type":"image","alt":"Pelthos Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Pelthos Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":179,"url":"https://media.zenfs.com/en/globenewswire.com/f94dd4c648565b20de109cac2516c355"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/k8zUsCvFBhGI4FW3YV9omg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI1MQ--/https://media.zenfs.com/en/globenewswire.com/f94dd4c648565b20de109cac2516c355","width":300,"height":179}},"lazy":false},{"type":"text","content":"ZELSUVMI™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total revenue including licensing revenue was $16.8 million for 2025. ","length":279,"tagName":"p"},{"type":"text","content":" 8,948 ZELSUVMI units prescribed by 2,712 unique prescribers for fiscal year 2025, with a 129% quarter over quarter increase in units dispensed, rising from 2,716 units in the third quarter of 2025 to 6,232 units in the fourth quarter of 2025.","length":242,"tagName":"p"},{"type":"text","content":"Management will host a conference call today at 8:00 a.m. EDT ","length":61,"tagName":"p"},{"type":"text","content":"DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos” or the “Company”), today announced its financial results for the fourth quarter and full year ended December 31, 2025, which can be found at the Financial Results section of the Company’s website at https://ir.pelthos.com/financial-info/financial-results.","length":477,"tagName":"p"},{"type":"text","content":"Recent and Full Year 2025 Highlights","length":36,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"ZELSUVMI, the first at home FDA-approved treatment for molluscum contagiosum (“MC”), a highly contagious viral skin infection that largely afflicts children, was launched in July 2025 and generated $16.2 million in net sales in the first two quarters of commercial operations, exceeding expectations.","length":300,"tagName":"p"}]},{"val":[{"type":"text","content":"From the launch of ZELSUVMI in July 2025 through December 31...